Salute e Benessere
VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia Care | DelveInsight
VUITY, developed by Allergan (now part of AbbVie), is a 1.25% pilocarpine hydrochloride ophthalmic solution designed to treat presbyopia in adults. It acts as a cholinergic muscarinic receptor agonist and comes as a sterile, isotonic, colorless solution. The active ingredient, pilocarpine hydrochloride, stimulates muscarinic receptors in smooth muscles such as the iris sphincter and ciliary muscle. This leads to contraction of the sphincter muscle, causing pupil constriction to enhance near and intermediate vision while preserving some light response. Additionally, it contracts the ciliary muscle, shifting the eye to a more myopic state.
VUITY's approval was based on two key Phase III trials, GEMINI 1 and GEMINI 2, which showed that it improved near and intermediate vision without compromising distance vision by helping the eye naturally reduce pupil size. It is the first and only US FDA-approved eye drop for presbyopia, a condition affecting nearly half of the US adult population. The drops are administered once daily using a proprietary PhAST technology, which enables quick adaptation to the eye's natural pH.
In March 2023 , the FDA approved a supplemental New Drug Application (sNDA) for VUITY, allowing for a second dose (one drop in each eye) to be applied 3 to 6 hours after the initial dose for enhanced presbyopia treatment in adults. The recommended dosage is one drop in each eye once daily, with the option for a second dose within the 3 to 6-hour window. VUITY contains 12.5 mg/mL of pilocarpine hydrochloride and is provided as a clear, sterile solution.
Learn more about VUITY projected market size for presbyopia @
Presbyopia is a common age-related vision problem characterized by a gradual decline in the ability to see up close, typically developing between the ages of 40 and 60. It occurs due to the lens losing its elasticity and becoming thicker, harder, and less flexible because of changes in structural proteins.
This reduces the lens's ability to adjust focus for near vision, leading to diminished accommodative amplitude. Presbyopia can be categorized into incipient, functional, absolute, premature, and nocturnal types, reflecting different stages and symptoms of the condition. According to DelveInsight, approximately cases of presbyopia were reported in the 7MM in 2023. This number is projected to grow at a notable from 2024 to 2034.
Treatment options primarily include corrective lenses and surgical procedures. Non-invasive solutions like reading glasses, bifocals, and progressive lenses improve vision at varying distances. Contact lenses, including multifocal and monovision types, provide another alternative. Surgical options such as LASIK, conductive keratoplasty, and corneal inlays adjust the eye's focusing ability. Recently, eye drops like pilocarpine hydrochloride have emerged as a promising treatment, temporarily enhancing near vision by constricting the pupil to increase depth of field.
DelveInsight projects that the presbyopia market size, valued at around in 2023, is expected to grow at a by 2034. This growth is driven by improvements in treatment options, better healthcare access, and a rising number of cases, fueling demand for more advanced and effective therapies.
Discover more about the presbyopia market in detail @
The presbyopia treatment landscape began to evolve with the approval of QLOSI (PresbiDrops (CSF-1)) in 2023, joining VUITY (pilocarpine hydrochloride ophthalmic solution) as the only FDA-approved therapies. Despite these approvals, the market remains underdeveloped, with limited competition on the horizon.
Key pipeline candidates include (Lenz Therapeutics) and (Visus Therapeutics and Tenpoint Therapeutics), both seeking to address these unmet needs. LNZ100's NDA has been accepted by the FDA, with a PDUFA date of August 8, 2025 , and no advisory committee meeting scheduled. BRIMOCHOL PF is expected to file its NDA in the first half of 2025, aiming for a US commercial launch in the first half of 2026 following anticipated FDA approval.
With only two approved therapies and a relatively weak pipeline, there remains a substantial market opportunity for new treatments that offer better efficacy, longer-lasting effects, or greater patient convenience.
To know more about the number of competing drugs in development, visit @
Discover how VUITY is shaping the presbyopia treatment landscape @
VUITY holds a first-mover advantage as the , giving it an established market presence and significant brand recognition among ophthalmologists and patients, which positions it as the before new entrants establish themselves. The largely underserved presbyopia market, with only one additional FDA-approved therapy (QLOSI) and a weak pipeline of emerging competitors, creates a significant growth opportunity for VUITY to expand its market share by .
However, may limit its appeal for some patients seeking all-day vision correction, potentially reducing adherence or satisfaction. Furthermore, the , which may offer longer duration, improved efficacy, or better tolerability, poses a competitive threat, requiring VUITY to adopt strategic efforts such as to maintain its market dominance.
Dive deeper to get more insight into VUITY's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key presbyopia companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including among others.
report delivers an in-depth understanding of market trends, market drivers, market barriers, and key myopia companies such as among others.
report provides comprehensive insights into pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myopia companies involved, such as among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
View original content: https://www.prnewswire.co.uk/news-releases/vuity-reports-strong-market-performance-setting-new-benchmark-in-presbyopia-care--delveinsight-302407746.html